Eqis Capital Management, Inc. Meridian Bioscience Inc Transaction History

Eqis Capital Management, Inc.

14 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 08, 2022	BUY	$23.75 - $31.69 $172,852 - $230,639	7,278 New	7,278 $221,000
Q2 2021 Aug 12, 2021	SELL	$18.01 - $28.32 $218,083 - $342,926	-12,109 Closed	0 $0
Q1 2021 May 14, 2021	BUY	$19.76 - $29.89 $36,852 - $55,744	1,865 Added 18.21%	12,109 $318,000
Q4 2020 Feb 11, 2021	SELL	$15.73 - $21.66 $77,108 - $106,177	-4,902 Reduced 32.36%	10,244 $191,000
Q3 2020 Nov 10, 2020	SELL	$13.54 - $26.41 $2,802 - $5,466	-207 Reduced 1.35%	15,146 $257,000
Q2 2020 Aug 10, 2020	BUY	$7.84 - $23.29 $120,367 - $357,571	15,353 New	15,353 $358,000
Q3 2019 Nov 05, 2019	SELL	$9.17 - $12.01 $283,297 - $371,036	-30,894 Closed	0 $0
Q2 2019 Jul 18, 2019	BUY	$10.88 - $17.6 $336,126 - $543,734	30,894 New	30,894 $367,000
Q1 2019 Apr 18, 2019	SELL	$15.51 - $17.61 $189,919 - $215,634	-12,245 Closed	0 $0
Q4 2018 Jan 25, 2019	SELL	$14.52 - $19.72 $72,425 - $98,363	-4,988 Reduced 28.94%	12,245 $213,000
Q3 2018 Oct 17, 2018	SELL	$14.85 - $16.35 $8,330 - $9,172	-561 Reduced 3.15%	17,233 $268,000
Q2 2018 Jul 27, 2018	BUY	$13.8 - $16.8 $245,557 - $298,939	17,794 New	17,794 $283,000
Q4 2017 Jan 25, 2018	SELL	$13.55 - $15.8 $174,131 - $203,045	-12,851 Closed	0 $0
Q3 2017 Oct 03, 2017	BUY	$13.45 - $14.35 $172,845 - $184,411	12,851	12,851 $184,000

113K

Ticker VIVO
Exchange NASDAQ
Sector Healthcare
Industry Diagnostics & Research
Shares Outstandng 43,748,000
Description
Meridian Bioscience, Inc., a life science company, develops, manufactures, distributes, and sells diagnostic test kits primarily for gastrointestinal and respiratory infectious diseases, and elevated blood lead levels worldwide. The company operates through Diagnostics and Life Science segments. The Diagnostics segment offers testing platforms, ...

Get notified when there are updates to the investment portfolio of Eqis Capital Management, Inc., based on Form 13F filings with the SEC.

Stay updated on Eqis Capital Management, Inc. with notifications on news.